Key result
Wearable cardioverter-defibrillators fail to significantly reduce 90-day mortality in post-MI patients.
Why the study?
Randomised evidence for wearable cardioverter-defibrillators after MI may not reflect patient characteristics and care pathways in Central and Eastern Europe, limiting direct applicability to local clinical practice.
Does a wearable cardioverter-defibrillator reduce 90-day all-cause death in a real-world Polish cohort of patients after myocardial infarction?
Observational (n=2,809)
Yes
Does a wearable cardioverter-defibrillator reduce 90-day all-cause death in a real-world Polish cohort of patients after myocardial infarction?
Transporting VEST trial evidence to a real-world Polish cohort yielded 90-day mortality estimates directionally consistent with the original trial, providing context-specific inference for wearable cardioverter-defibrillator implementation where local randomized data are lacking.
Answers are grounded in this paper and cite their sources.
WCD use was not associated with lower 90-day mortality in this transported Polish cohort; leaves open the need for local randomized trials before adoption.
Background/Introduction Randomised evidence for wearable cardioverter-defibrillators (WCDs) after myocardial infarction (MI) may not reflect patient characteristics and care pathways in Central and Eastern Europe, limiting the direct applicability of trial findings to local clinical practice. Purpose To estimate the 90-day effect of a WCD on mortality when evidence from the VEST randomised trial is transported to a Polish target population using anchored transportability analysis. Methods Individual participant data from VEST (1) (n=2,302; intention-to-treat) were combined with two Polish observational cohorts (pooled target n=507 adults) (2,3). The primary endpoint was all-cause death at 90 days and sudden death served as a secondary endpoint (arrhythmic death proxy). We computed stabilised inverse-odds-of-participation weights from a logistic selection model including age, sex, body mass index, and baseline left ventricular ejection fraction, with median imputation and missingness indicators; weights were trimmed at the 1st/99th percentiles. Transported risks, risk differences (RDs) and risk ratios (RRs) were estimated by weighted standardisation, with uncertainty quantified by nonparametric bootstrap (B=1,000) resampling both source and target datasets and refitting weights at each replicate. Results Covariate overlap was high (trial weight range 0.47–1.16; median 0.93). In the transported Polish population, 90-day all-cause mortality was 3.23% with WCD versus 5.03% with control (RD −1.80 percentage points [pp]; 95% bootstrap CI −4.81 to 1.14; RR 0.64; 95% CI 0.33–1.37). Sudden death occurred in 1.50% versus 2.15% (RD −0.65 pp; 95% CI −2.85 to 1.18; RR 0.70; 95% CI 0.26–2.17). A sensitivity analysis restricted to VEST participants recruited in Central/Eastern Europe (n=632) was directionally consistent (RD −2.28 pp; 95% CI −5.81 to 0.70; RR 0.52; 95% CI 0.18–1.24). Conclusion(s) Transporting VEST evidence to a real-world Polish cohort yielded mortality estimates directionally consistent with the original trial, supported by strong covariate overlap and stable transportability weights. Confidence intervals crossing the null reflect limited local sample size rather than absence of effect. This transportability framework enables context-specific inference and can inform WCD implementation and policy decisions where local randomised evidence is unavailable.
No takes yet. Share an insight, caveat, or question.
Mitkowski et al. (2026) conducted an observational in Post-myocardial infarction (n=2,809). Wearable cardioverter-defibrillator (WCD) vs. Control (no WCD) was evaluated on All-cause death at 90 days (RR 0.64, 95% CI 0.33-1.37). Wearable cardioverter-defibrillators transported to a Polish post-MI cohort yielded 90-day mortality of with control.
Synapse has enriched 10 related papers. Consider them for comparative context: